3D-Health Research, Barcelona, Spain.
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):151-7. doi: 10.1586/14737167.8.2.151.
In the framework of an integral assessment (effectiveness and cost) of the use of neuroprotection in stroke, a cost-effectiveness study was conducted to compare the potential advantages of citicoline with conventional therapy (without neuroprotection or placebo) in patients with acute ischemic stroke. The literature was searched for systematic reviews and meta-analyses evaluating the effectiveness of citicoline versus placebo in the hospital setting and during 12 weeks after discharge from hospital. Data on the use of resources were obtained from a panel of experts of four acute-care teaching hospitals in Spain. The study was performed from the perspective of the Spanish National Health System. Two meta-analyses were included (Cochrane Stroke Review Group and a pooling analysis). Treatment with citicoline resulted in 99 or 50 more patients recovered per 1000 patients treated (depending on selection criteria of the Cochrane study and the pooled analysis), with average cost savings between euro101.2 and euro126.4 per patient treated of the type of those included in the Cochrane study. In patients with acute ischemic stroke, treatment with placebo was more expensive and less effective in the scenarios of inpatient care and inpatient plus outpatient care after discharge from the hospital.
在对卒中使用神经保护进行整体评估（效果和成本）的框架内，进行了一项成本效益研究，以比较胞磷胆碱与常规治疗（无神经保护或安慰剂）在急性缺血性卒中患者中的潜在优势。检索了评估胞磷胆碱与安慰剂在医院环境中以及出院后 12 周内效果的系统评价和荟萃分析的文献。资源使用数据来自西班牙四家急性护理教学医院的专家小组。该研究从西班牙国家卫生系统的角度进行。纳入了两项荟萃分析（Cochrane 卒中综述组和汇总分析）。与使用安慰剂相比，使用胞磷胆碱治疗可使每 1000 名治疗患者中增加 99 或 50 名康复患者（取决于 Cochrane 研究的选择标准和汇总分析），每例治疗患者的平均节省成本在 101.2 欧元至 126.4 欧元之间，属于 Cochrane 研究中包含的那种类型。在急性缺血性卒中患者中，在住院治疗和出院后门诊治疗的情况下，使用安慰剂治疗更昂贵且效果更差。
